ArticleBMC infectious diseases2025
Tracking acute flaccid paralysis in Niger: a half-decade epidemiological portrait (2016-2021).
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ethiopia towards polio eradication: insights from acute flaccid paralysis surveillance data analysis 2016 to 2023.The Pan African medical journal · 2026Article
- A review on health system-based surveillance for acute flaccid paralysis: technological advancements, challenges, and outlooks.Journal of health, population, and nutrition · 2025Review
- Community-Based Surveillance of Acute Flaccid Paralysis: A Review on Detection and Reporting Strategy.Journal of epidemiology and global health · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundRecently, a total of 74 circulating vaccine-derived poliovirus (cVDPV) outbreaks were detected in 39 countries, with 672 confirmed Acute Flaccid Paralysis (AFP) cases identified in 27 countries. Despite progress, Niger experienced cVDPV outbreaks in 2018, highlighting the importance of maintaining AFP surveillance as a tool for polio eradication. This analysis aims to comprehensively assess AFP surveillance trends, patterns, and challenges in Niger, offering insights for public health initiatives in conflict-affected contexts.
methodsWe analyzed nationwide AFP surveillance data from 2016 to 2021. The data included information about the person's background, vaccinations, medical history, cVDPV, AFP cases, stool samples, how quickly AFP cases were reported, how complete weekly zero reporting (WZR) was, and non-polio enteroviruses (NPEV). Tables, graphs, and maps presented the study findings.
resultsA total of 4,134 AFP cases under 15 years old were included, with a sex ratio of 1.3. Most cases (79.85%) were aged 1 to 4 years, and 79.44% received three or more doses of oral polio vaccine (OPV). Fever onset (90.13%), asymmetric paralysis (80.33%), and a 3-day AFP progression (80.48%) were common. cVDPV2 was found in 33 cases, predominantly in Zinder province. The annualized non-polio AFP rate per 100,000 population < 15 years fluctuated, with the lowest at 2.5 in 2016 and highest at 8.7 in 2018 (mean 5.93). Surveillance indicators, including faecal specimen collection, follow-up exams, NPEV detection, timeliness of AFP case notification, WZR, and timely laboratory results performed above the set target. However, stool specimen quality was suboptimal (69% in 2016), timeliness of AFP case investigation and contact sampling, and stool transportation times were below the set target. Five districts reported less than 80% stool adequacy.
conclusionThis study underscores the importance of continued AFP surveillance in Niger, with room for improvement in stool specimen quality and transportation times. Enhancing these aspects can improve public health efforts in conflict-affected areas and contribute to polio eradication in the region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.